"10/13/2014 Richard L. Chang (Seller) Rich Pharmaceuticals (Buyer) Rich Pharmaceuticals is purchasing IP rights related to using RP-323 to treat Hodgkin's lymphoma from Richard L. Chang Holdings"
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.